Harbour Capital Advisors, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Harbour Capital Advisors, LLC
- $415 Million
- Q3 2024
A detailed history of Harbour Capital Advisors, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Harbour Capital Advisors, LLC holds 4,550 shares of CRNX stock, worth $230,502. This represents 0.06% of its overall portfolio holdings.
Number of Shares
4,550
Previous 4,550
-0.0%
Holding current value
$230,502
Previous $203,000
14.29%
% of portfolio
0.06%
Previous 0.05%
Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$319 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$316 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$298 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$251 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$226 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.72B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...